Limitations, agreements, and source contact

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

gerecitj@mskcc.org

organization

Memorial Sloan Kettering Cancer Center

phone

212-639-3748

title

Dr. John Gerecitano

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice